Healthcare
Beyond Air, Inc.(XAIR)
Live Price
Offline$0.36
-1.91% today
1Y Change
-90.89%
Window
Jun 23, 2025 โ Jun 16, 2026
- Market Cap
- โ
- Revenue Growth
- +219.7%
- EPS Growth
- +62.1%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 23, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Beyond Air, Inc. (XAIR) is a Healthcare stock with listed on NASDAQ. The stock last traded around $0.36 and down 90.9% across the available one-year price window (Jun 23, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of +219.7%, EPS growth of +62.1%, a dividend yield of 0.0%. What stands out right now is revenue +219.7%, EPS +62.1%, free cash flow +28.6% with operating margin -419.5% and ROIC -90.3%. Valuation is more restrained than many high-expectation growth names at price/sales 0.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines XAIR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+219.7% vs +7.6% peer median
Operating Margin
Below sector median
-419.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Feb 13, 2026 with an EPS surprise of -13.3% and a revenue surprise of +1.9%.
The operating story is still moving forward
Revenue is running at +219.7% and EPS at +62.1%, with operating margin around -419.5%.
The next real check-in already has a date
The next earnings event is scheduled for Jun 29, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -18.1% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 13, 2026 | -13.3% | +2.9% | -3.8% | -21.0% |
2025 Nov 10, 2025 | -131.5% | -16.1% | -23.0% | -33.9% |
2025 Aug 12, 2025 | -2.0% | -22.5% | -27.5% | -28.5% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XAIR
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
XAIR Max Drawdown
-91.77%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for XAIR and SPY.
Company Overview
Beyond Air, Inc.
NASDAQ Capital Market
Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
- Leadership
- Amir Avniel
- IPO Date
- Jun 12, 2018
- Employees
- 107
- Street Address
- 900 Stewart Avenue
- Mailing
- Garden City, NY, 11530
- Region
- Garden City, NY, US
- Reporting Currency
- USD
- Investor Line
- 516 665 8200
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.4
- Price/Book
- 0.6
Growth
- Revenue
- +219.7%
- EPS
- +62.1%
- Free Cash Flow
- +28.6%
Profitability
- Gross Margin
- 1.8%
- Operating Margin
- -419.5%
- Net Margin
- -447.7%
- ROE
- -279.6%
- ROIC
- -90.3%
Balance Sheet
- Debt/Equity
- 3.06
- Current Ratio
- 5.12
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.